Oct 2026· Scientific Reports· Vol 16· 0 citations· 33 references
TL;DR
It is concluded that MAFLD was independently associated with accelerated kidney function decline and increased CKD risk over 16 years, highlighting the importance of kidney function monitoring in individuals with MAFLD.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with chronic kidney disease (CKD), but its long-term impact on kidney function remains unclear. We investigated the association between MAFLD and kidney outcomes over 16 years using data from the Korean Genome and Epidemiology Study. Among 10,030 participants aged 40–69 years recruited in 2001–2002, 8,827 with sufficient baseline and follow-up data were included. MAFLD was defined using the fatty liver index (FLI ≥ 30) combined with metabolic criteria. The primary outcome was the longitudinal estimated glomerular filtration rate (eGFR) slope assessed using linear mixed-effects models. The secondary outcome was incident CKD (eGFR < 60 ml/min/1.73 m2). At baseline, 45.1% (n = 3,978) had FLI-defined MAFLD. Over 16 years, the median annual eGFR decline was − 0.61 mL/min/1.73 m2 per year. After multivariable adjustment, MAFLD was independently associated with accelerated eGFR decline (β: −0.29; 95% CI:−0.39 to − 0.18; P < 0.001). During a median follow-up of 15.4 years, 19.5% (n = 1,662) developed CKD, and MAFLD was associated with a 26% increased risk of incident CKD (hazard ratio: 1.26, 95% CI: 1.11–1.43; P < 0.001). Higher FLI categories were associated with progressively steeper eGFR decline. In conclusion, MAFLD was independently associated with accelerated kidney function decline and increased CKD risk over 16 years, highlighting the importance of kidney function monitoring in individuals with MAFLD.
ABSTRACT Aim Both high and low body mass index (BMI) have been reported to be associated with a higher risk of chronic kidney disease (CKD) progression. However, whether this association varies across CKD stages remains unclear. We hypothesized that the association between BMI and renal outcomes varies according to kid...
R. Inoue, Satoko Yamaguchi, A. Okada et al.· Nephrology· 0 citations
Type 2 diabetes is the leading cause of end-stage kidney disease (ESKD), yet long-term trajectories of kidney function from the time of diagnosis‐particularly in individuals with preserved kidney function and no albuminuria‐remain poorly characterized. We aimed to evaluate the long-term risks of incident albuminuri...
H. Kim, Seok-Jae Heo, Samel Park et al.· Frontiers in Endocrinology· 0 citations
In a large, nationally representative cohort, renal function exhibited stable and significant inverse associations with non-invasive hepatic fibrosis indices across nearly two decades, highlighting population-level coupling between kidney function, hepatic risk scores, and metabolic traits.
Amr Elhamamsy, Yu-Sheng Zhu· Clinical Chemistry· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in older adults, yet its independent contribution to cognitive decline beyond cardiometabolic risk factors remains uncertain.
METHODS
We performed a cross-sectional analysis of 1,387 NHANES 2011-2014 participants aged ≥60 years....
Mohammad Aldiabat, Y. Al Jabiri, W. Aleyadeh et al.· American Journal of the Medi...· 0 citations
Background Diabetic kidney disease (DKD) is a dominant driver of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Current risk assessment tools, however, lack adequate sensitivity for early disease detection. This study evaluated the prognostic value of multiple biomarkers for kidney function decline in...
Jie Hu, Xin-Yu Pan, Shu-Wu Wei et al.· Frontiers in Endocrinology· 0 citations
Background Cardiovascular disease is a major extrahepatic outcome in type 2 diabetes mellitus (T2DM) and metabolic fatty liver disease, but prospective data integrating transient elastography and the fibrosis-4 index (FIB-4) with observed cardiovascular events remain limited in Southeast Asia. Methods We conducted a pr...
Quốc Bảo Vũ, Hồng Minh Công Võ, Xuân Linh Trần et al.· Frontiers in Gastroenterolog...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.